Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”), today announced that it has granted
a non-exclusive license to IDEXX Laboratories, Inc, to use Exiqon's proprietary
LNA™ technology in defined products for veterinary disease diagnostics.

Exiqon will receive upfront and milestones payments, and royalty on global
sales of the products covered by this agreement. Financial terms of the
agreement were not disclosed.

“We are pleased to see IDEXX Laboratories has chosen to apply Exiqon's
proprietary technology in the field of veterinary diagnostics” said Lars
Kongsbak, CEO & President of Exiqon. ”We are excited that the LNA™ technology
is now being applied in veterinary diagnostic products which emphasizes the
broad applicability of the LNA™ technology”.

LNA™ provides unique characteristics to molecular assays and offers many
possibilities for developing competitive products. It is therefore an inherent
part of Exiqon's strategy through license agreements to capitalize on its
proprietary LNA™ technology within market segments that Exiqon does not plan to
pursue itself.


Additional information
Exiqon A/S

Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)

Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)

Announcement_16_IDEXX_EXQ.pdf